CA-125 Response Patterns in Patients With Recurrent Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (PLD). Issue 1 (1st January 2010)

• Record Type: Journal Article
• Authors: Oaknin, Ana; Barretina, Pilar; Pérez, Xavier; Jimenez, Laura; Velasco, Montserrat; Alsina, Maria; Brunet, Joan; GermÀ, Josep Ramon; Beltran, Miguel
• Is Part Of: International journal of gynecological cancer. Volume 20:Issue 1(2010)
• Page Start: 87-91
• Page End: 87-91
• Publication Date: 2010-01-01
• Subjects: CA-125 -- Ovarian cancer -- Pegylated liposomal doxorubicin -- Recurrent; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1111/IGC.0b013e3181c16ba1
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction: In recurrent ovarian cancer, CA-125 could be the only objective response criteria. This study analyzes response patterns regarding CA-125 in responders versus nonresponders and determines whether a specific cutoff value for CA-125 could predict clinical response, compared with response evaluation criteria in solid tumors, in patients receiving pegylated liposomal doxorubicin (PLD). Methods: Sixty-eight patients were identified, 78% were platinum resistant. Relative changes in CA-125 values were calculated, and response was defined as higher than 50% reduction in CA-125 from baseline. Receiver operating characteristic (ROC) curves were constructed based on CA-125 value after the first cycle of PLD to evaluate the most precise cutoff point for the decision model predicting response. Results: Fifty-three patients were assessable for response: 16 patients responded and 37 did not; the median increase of CA-125 was 0.20 (−63; 312) and 52 (−29; 620), respectively. Our ROC curve generated a cutoff value with a sensitivity of 35% (positive test, the proportion of patients who will not respond) and a predictive positive value of 80%. According to the predictive positive value, 20% of the responder patients will be identified as nonresponders; P = 0.025. Conclusions: Our ROC analysis did not demonstrate any reliable CA-125 cutoff on response. Discontinuation of the therapy before cycle 3 may exclude some patients who will benefit from PLD.